

Article

Bioactivity of Novel Pyrazole-Thiazolines Scaffolds against *Trypanosoma cruzi*: Computational Approaches and 3D Spheroid Model on Drug Discovery for Chagas Disease

Leonardo da Silva Lara ¹, Guilherme Curty Lechuga ¹, Lorraine Martins Rocha Orlando ¹,
Byanca Silva Ferreira ², Bernardo Araújo Souto ², Maurício Silva dos Santos ²
and Mirian Claudia de Souza Pereira ^{1,*}

- ¹ Laboratório de Ultraestrutura Celular, Instituto Oswaldo Cruz, Fiocruz, Av. Brasil 4365, Manguinhos, Rio de Janeiro 21040-900, Brazil; leonardosilva.lara@hotmail.com (L.d.S.L.); guilherme.lechuga@yahoo.com.br (G.C.L.); lorrainemartins07@hotmail.com (L.M.R.O.)
- ² Laboratório de Síntese de Sistemas Heterocíclicos (LaSSH), Instituto de Física e Química, Universidade Federal de Itajubá, Avenida BPS, 1303, Pinheirinho, Itajubá 37500-903, Brazil; byancaferreira@outlook.com (B.S.F.); araujoso@ualberta.ca (B.A.S.); mauriciosantos@unifei.edu.br (M.S.d.S.)
- * Correspondence: mirian@ioc.fiocruz.br; Tel.: +55-21-2562-1023; Fax: +55-21-2562-1019

Abstract: Chagas disease, a century-old disease that mainly affects the impoverished population in Latin America, causes high morbidity and mortality in endemic countries. The available drugs, benznidazole (Bz) and nifurtimox, have limited effectiveness and intense side effects. Drug repurposing, and the development of new chemical entities with potent activity against *Trypanosoma cruzi*, are a potential source of therapeutic options. The present study describes the biological activity of two new series of pyrazole-thiazoline derivatives, based on optimization of a hit system 5-aminopyrazole-imidazole previously identified, using structure–activity relationship exploration, and computational and phenotype-based strategies. Promising candidates, **2c**, **2e**, and **2i** derivatives, showed good oral bioavailability and ADMET properties, and low cytotoxicity (CC₅₀ > 100 μM) besides potent activity against trypomastigotes (0.4–2.1 μM) compared to Bz (19.6 ± 2.3 μM). Among them, **2c** also stands out, with greater potency against intracellular amastigotes (pIC₅₀ = 5.85). The selected pyrazole-thiazoline derivatives showed good permeability and effectiveness in the 3D spheroids system, but did not sustain parasite clearance in a washout assay. The compounds' mechanism of action is still unknown, since the treatment neither increased reactive oxygen species, nor reduced cysteine protease activity. This new scaffold will be targeted to optimize in order to enhance its biological activity to identify new drug candidates for Chagas disease therapy.

Keywords: *Trypanosoma cruzi*; pyrazole; thiazoline; chemotherapy; Chagas disease



Citation: Lara, L.d.S.; Lechuga, G.C.; Orlando, L.M.R.; Ferreira, B.S.; Souto, B.A.; dos Santos, M.S.; Pereira, M.C.d.S. Bioactivity of Novel Pyrazole-Thiazolines Scaffolds against *Trypanosoma cruzi*: Computational Approaches and 3D Spheroid Model on Drug Discovery for Chagas Disease. *Pharmaceutics* **2022**, *14*, 995. <https://doi.org/10.3390/pharmaceutics14050995>

Academic Editors: Juan José Torrado and Arnobio A. da Silva-Junior

Received: 10 February 2022

Accepted: 22 February 2022

Published: 5 May 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Chagas disease (CD) is a potentially fatal infection, caused by the flagellated protozoan *Trypanosoma cruzi*, that affects about 6–7 million people worldwide, leading to more than 10,000 annual deaths [1]. This pathology is considered a serious public health problem, representing one of the biggest causes of heart failure and sudden death in many endemic countries in Latin America [2].

With the increase in migratory mobility, the disease has been increasingly reported in non-endemic countries, such as Canada, Australia, Spain, Japan, and the United States of America, among others [3]. As a result of areas with active transmission, and the high number of people without diagnosis and treatment, it is estimated that 75 million people are at risk of infection [1].

Although vector-borne transmission, which occurs during the blood meal of triatomine bugs, has been mostly controlled in some endemic countries [4], *T. cruzi* oral infection,

by ingestion of food contaminated with infected triatomines or their feces, in addition to congenital (mother-to-child) *T. cruzi* infection, emerged as potential transmission routes [5].

The acute phase of the disease, characterized by positive parasitemia, lasts approximately 60 days, usually with mild and nonspecific symptoms, which can make diagnosis and early treatment difficult [6,7]. About 30–40% of infected individuals will develop a chronic symptomatic phase, characterized by serious cardiac, digestive, neurological, or mixed clinical manifestations, which cause significant morbidity and mortality [1,8].

The available etiological treatment is restricted to two antiparasitic drugs: benznidazole (Bz) and nifurtimox (Nif), which were clinically introduced more than 50 years ago. Both drugs are partially effective in acute cases (60–80%), in congenital cases, and in reactivation by immunosuppression [9]. However, the occurrence of serious adverse effects and the long-term treatment period often lead to treatment discontinuity [10,11]. To date, clinical trials pointed to the low efficacy of Bz and Nif in the chronic phase of the disease [12]. The BENznidazole Evaluation for Interrupting Trypanosomiasis (BENEFIT) trial, a randomized placebo-controlled clinical trial with patients in the chronic phase of Chagas disease, revealed the failure of Bz to inhibit the chronic Chagas cardiomyopathy progression [13]. Therapeutic failure of the most promising azole candidates, ergosterol biosynthesis inhibitors, has been reported in phase II randomized clinical trials [14,15]. Monotherapy with posaconazole [14] and fosravuconazole (E1224) [15] did not show efficacy, but only a temporary suppression of the parasite burden. Furthermore, the combination therapy of Bz with posaconazole has shown no additional benefits compared to Bz monotherapy [16]. The data from the BENznidazole New Doses Improved Treatment and Associations (BENDITA) trial brought a new perspective of treatment with Bz, showing efficacy with low doses and short treatment schedules [17]. Fexinidazole, a drug approved for human African trypanosomiasis [18], sustained trypanocidal activity, but the treatment was interrupted due to safety and tolerability issues. Thus, a new fexinidazole clinical study was conducted with a low-dose, short-term treatment regimen, which was expected to be completed in 2021 [19]. This scenario highlights the urgent need for new, safer, and more efficient drugs for the treatment of Chagas disease.

Pyrazoles and their derivatives stand out in the field of medicinal chemistry [20], as they represent a relevant class of compounds with broad biological activities already reported as antioxidants [21], antiviral [22], antimicrobial [23], anticancer [24], and anti-inflammatory [25], among others. Pyrazole derivatives have been highlighted for their effects on trypanosomatids [26]. Pyrazole-trifluoromethylated hybrids have potent activity against *Leishmania amazonensis* and *T. cruzi*, with the pyrazole 2-amino-1,3,4-thiadiazole hybrids considered as a relevant scaffold for optimization [27]. The in vitro biological activity of dialkyl pyrazole-3,5-dicarboxylates analogues has also been demonstrated against *T. cruzi*, *Leishmania infantum* and *Leishmania braziliensis*, showing a remarkable inhibition of iron superoxide dismutase (Fe-SOD) activity that is responsible for the antioxidant defense mechanism of the parasite. Two analogues showed efficacy in a murine model of acute and chronic Chagas disease, with suppressive activity on the parasitemia (95%) even after animal immunosuppression [28]. Additionally, potent trypanocidal activity was evidenced by *N*-ethylurea pyrazole derivatives against *T. brucei* and *T. cruzi*, drastically reducing the parasitic burden in experimental acute infection by *T. cruzi* [29]. Also, we have recently reported the trypanocidal activity of pyrazole-imidazoline derivatives, showing low mammalian cell toxicity, and a prediction of good oral bioavailability by in silico analysis of physicochemical and ADMET properties [30]. The promising analogues bind by hydrogen bond and hydrophobic interactions to the active site of cruzipain, and significantly inhibit cysteine protease activity. These derivatives have been used by our research group as a hit system to synthesize new compounds through rational optimization, including ring bioisosterism, functional group interconversion, and functional group removal [30,31].

In this study, we demonstrate the trypanocidal activity and computational data of two new series of pyrazole-thiazoline derivatives, **1(a-1)** and **2(a-1)**. A three-dimensional (3D)

in vitro model and reversibility assay were also performed to evaluate the permeability and efficacy in microtissue and parasite recrudescence.

2. Materials and Methods

2.1. Chemistry

All reagents and solvents were used without further purification. The reactions were followed by thin layer chromatography on silica gel-precoated aluminum plates (type 60-F254). Melting points are uncorrected, and were determined on a Fisatom 430 (Fisatom, São Paulo, SP, Brazil) or Allerbest PF0100 (Allerbest, Curitiba, PR, Brazil) equipment. FT-IR spectra were acquired on a PerkinElmer Spectrum 100, ATR diamond-ZnSe apparatus (PerkinElmer, Waltham, MA, USA). NMR spectra were performed on a Bruker Avance (Bruker, Rheinstetten, Germany), 400 or 500 MHz, at 298 K, CDCl₃ as solvent, and TMS as internal reference. Chemical shifts (δ) are expressed in parts per million (ppm), and coupling constants (J) in Hertz (Hz). HRMS spectra were recorded on a Micromass/Waters ZQ-4000 spectrometer (Waters, Milford, MA, USA) (Supplementary Figure S1).

The key intermediates, 5-amino-1-aryl-1H-pyrazole-4-carbonitriles **4(a-1)** and 1-aryl-1H-pyrazole-4-carbonitriles **5(a-1)**, were synthesized by our research group according to the methodologies previously published [32,33].

General procedure for synthesis of 2-(5-amino-1-aryl-1H-pyrazole-4-yl)-4,5-dihydrothiazoles 1(a-1) and 2-(1-aryl-1H-pyrazole-4-yl)-4,5-dihydrothiazoles 2(a-1)

A mixture of 2-aminoethanethiol hydrochloride (2 mmol), potassium carbonate (1 mmol), and methanol (5 mL) was stirred and refluxed for 30 min. Subsequently, the key intermediate, **4(a-1)** or **5(a-1)** (1 mmol), was added, and the reaction was accompanied by TLC. After 3–6 h, the mixture was poured into cold water. The product was filtered out and washed with cold water. In order to facilitate the assignment of signals in ¹H NMR spectra, the hydrogen atoms of compounds **1(a-1)** and **2(a-1)** were highlighted (Figures 1 and 2).




Figure 1. Molecular structure of series **1(a-1)** with hydrogen atoms highlighted.

2-(5-amino-1-phenyl-1H-pyrazol-4-yl)-4,5-dihydrothiazole (1a)

Yield: 87%. m.p.: 176–178 °C. FT-IR ν (cm⁻¹): 3342, 3249, 3184, 3052, 2937, 2855, 1600, 1546–1454. ¹H NMR (400 MHz, CDCl₃) δ 7.61 (s, H₃), 7.58–7.49 and 7.41–7.37 (m, H₂'-H₆'), 5.67 (br, NH₂), 4.33 (t, J = 8.0 Hz, H₄''), 3.34 (t, J = 8.0 Hz, H₅''). ¹³C NMR (100 MHz, CDCl₃) δ 161.8, 145.8, 140.5, 137.9, 129.7, 127.9, 123.6, 99.2, 63.7, 33.0. HRMS (ESI) m/z [M+H]⁺ = 245.0856 (found), [M+H]⁺ = 245.0855 (calculated).




Figure 2. Molecular structure of series **2(a-l)** with hydrogen atoms highlighted.

2-(5-amino-1-(3-chlorophenyl)-1H-pyrazol-4-yl)-4,5-dihydrothiazole (1b)

Yield: 90%. m.p.: 186–189 °C. FT-IR ν (cm⁻¹): 3346, 3265, 3194, 3068, 2938, 2855, 1596, 1544–1442. ¹H NMR (400 MHz, CDCl₃) δ 7.62 (t, *J* = 2.0 Hz, H_{2'}), 7.60 (s, H₃), 7.50–7.48 (m, H_{6'}), 7.43 (t, *J* = 7.9 Hz, H_{5'}), 7.37–7.34 (m, H_{4'}), 5.72 (br, NH₂), 4.33 (t, *J* = 8.1 Hz, H_{4''}), 3.34 (t, *J* = 8.1 Hz, H_{5''}). ¹³C NMR (100 MHz, CDCl₃) δ 161.7, 145.9, 140.9, 139.1, 135.5, 130.7, 127.9, 123.7, 121.2, 99.5, 63.7, 33.1. HRMS (ESI) *m/z* [M+H]⁺ = 279.0460 (found), [M+H]⁺ = 279.0466 (calculated).

2-(5-amino-1-(2,4-dichlorophenyl)-1H-pyrazol-4-yl)-4,5-dihydrothiazole (1c)

Yield: 88%. m.p.: 209–212 °C. FT-IR ν (cm⁻¹): 3323, 3240, 3184, 3135, 2941, 2855, 1603, 1548–1434. ¹H NMR (400 MHz, CDCl₃) δ 7.64 (s, H₃), 7.59–7.58 (m, H_{3'}), 7.41 (m, H_{5'}, H_{6'}), 5.49 (br, NH₂), 4.32 (t, *J* = 8.0 Hz, H_{4''}), 3.34 (t, *J* = 8.0 Hz, H_{5''}). ¹³C NMR (100 MHz, CDCl₃) δ 161.7, 147.1, 141.2, 136.3, 133.6, 133.0, 130.7, 130.6, 128.5, 98.5, 63.7, 33.1. HRMS (ESI) *m/z* [M+H]⁺ = 313.0072 (found), [M+H]⁺ = 313.0076 (calculated).

2-(5-amino-1-(3,5-dichlorophenyl)-1H-pyrazol-4-yl)-4,5-dihydrothiazole (1d)

Yield: 81%. m.p.: 232–234 °C. FT-IR ν (cm⁻¹): 3410, 3293, 3087, 3070, 2929, 2850, 1584, 1522–1429. ¹H NMR (400 MHz, CDCl₃) δ 7.60 (s, H₃), 7.55 (d, *J* = 1.8 Hz, H_{2'}, H_{6'}), 7.36 (t, *J* = 1.8 Hz, H_{4'}), 5.74 (br, NH₂), 4.33 (t, *J* = 8.1 Hz, H_{4''}), 3.34 (t, *J* = 8.1 Hz, H_{5''}). ¹³C NMR (100 MHz, CDCl₃) δ 161.3, 146.0, 141.2, 139.9, 136.0, 127.6, 121.4, 99.9, 63.9, 33.1. HRMS (ESI) *m/z* [M+H]⁺ = 313.0067 (found), [M+H]⁺ = 313.0076 (calculated).

2-(5-amino-1-(3,4-dichlorophenyl)-1H-pyrazol-4-yl)-4,5-dihydrothiazole (1e)

Yield: 90%. m.p.: 279–282 °C. FT-IR ν (cm⁻¹): 3315, 3248, 3088, 3069, 2946, 2860, 1593, 1543–1430. ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.83 (d, *J* = 2.5 Hz, H_{2'}), 7.77 (d, *J* = 8.7 Hz, H_{5'}) 7.59 (s, H₃), 7.61–7.59 (m, H_{6'}), 6.69 (br, NH₂), 4.26 (t, *J* = 8.0 Hz, H_{4''}), 3.33 (t, *J* = 8.0 Hz, H_{5''}). ¹³C NMR (100 MHz, DMSO-*d*₆) δ 159.8, 146.8, 140.6, 137.8, 131.6, 131.1, 129.4, 124.6, 123.1, 98.3, 63.6, 32.2. HRMS (ESI) *m/z* [M+H]⁺ = 313.0074 (found), [M+H]⁺ = 313.0076 (calculated).

2-(5-amino-1-(4-chlorophenyl)-1H-pyrazol-4-yl)-4,5-dihydrothiazole (1f)

Yield: 82%. m.p.: 283–285 °C. FT-IR ν (cm⁻¹): 3328, 3240, 3184, 3144, 3065, 2932, 2856, 1603, 1545–1432. ¹H NMR (400 MHz, CDCl₃) δ 7.60 (s, H₃), 7.53 (d, *J* = 8.8 Hz, H_{2'}, H_{6'}), 7.48 (d, *J* = 8.8 Hz, H_{3'}, H_{5'}), 5.67 (br, NH₂), 4.33 (t, *J* = 8.0 Hz, H_{4''}), 3.34 (t, *J* = 8.0 Hz, H_{5''}). ¹³C NMR (100 MHz, CDCl₃) δ 161.8, 145.9, 140.7, 136.5, 133.6, 129.9, 124.8, 99.4, 63.6, 33.0. HRMS (ESI) *m/z* [M+H]⁺ = 279.0464 (found), [M+H]⁺ = 279.0466 (calculated).

2-(5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl)-4,5-dihydrothiazole (1g)

Yield: 86%. m.p.: 244–246 °C. FT-IR ν (cm⁻¹): 3342, 3254, 3194, 3141, 2947, 2858, 1599, 1547–1434. ¹H NMR (400 MHz, CDCl₃) δ 7.59 (s, H₃), 7.56–7.52 (m, H_{2'}, H_{6'}), 7.20 (t,

$J = 8.6$ Hz, H_3' , H_5'), 5.57 (br, NH_2), 4.32 (t, $J = 8.0$ Hz, H_4''), 3.33 (t, $J = 8.0$ Hz, H_5''). ^{13}C (100 MHz, $CDCl_3$) δ 161.8 (d, $J = 248.4$ Hz), 161.5, 145.9, 140.4, 134.0 (d, $J = 3.0$ Hz), 125.7 (d, $J = 8.7$ Hz), 116.7 (d, $J = 23.0$ Hz), 99.4, 63.9, 33.1. HRMS (ESI) m/z $[M+H]^+ = 263.0758$ (found), $[M+H]^+ = 263.0761$ (calculated).

2-(5-amino-1-(3-fluorophenyl)-1H-pyrazol-4-yl)-4,5-dihydrothiazole (1h)

Yield: 94%. m.p.: 230–232 °C. FT-IR ν (cm^{-1}): 3333, 3256, 3078, 2944, 2858, 1603, 1544–1438. 1H NMR (400 MHz, $CDCl_3$) δ 7.60 (s, H_3), 7.50–7.44 (m, H_6'), 7.40–7.38 (m, H_5'), 7.37–7.33 (m, H_4'), 7.11–7.08 (m, H_2'), 5.73 (br, NH_2), 4.33 (t, $J = 8.1$ Hz, H_4''), 3.34 (t, $J = 8.1$ Hz, H_5''). ^{13}C (100 MHz, $CDCl_3$) δ 163.1 (d, $J = 248.4$ Hz), 161.6, 145.9, 140.8, 139.4 (d, $J = 10.0$ Hz), 131.0 (d, $J = 9.1$ Hz), 118.6 (d, $J = 3.3$ Hz), 114.7 (d, $J = 21.1$ Hz), 111.0 (d, $J = 24.8$ Hz), 99.5, 63.8, 33.1. HRMS (ESI) m/z $[M+H]^+ = 263.0765$ (found), $[M+H]^+ = 263.0761$ (calculated).

2-(5-amino-1-(4-bromophenyl)-1H-pyrazol-4-yl)-4,5-dihydrothiazole (1i)

Yield: 80%. m.p.: 282–284 °C. FT-IR ν (cm^{-1}): 3339, 3260, 3210, 3066, 2939, 2853, 1604, 1579–1425. 1H NMR (400 MHz, $CDCl_3$) δ 7.63 (d, $J = 8.8$ Hz, H_3' , H_5'), 7.60 (s, H_3), 7.47 (d, $J = 8.8$ Hz, H_2' , H_6'), 5.68 (br, NH_2), 4.33 (t, $J = 8.0$ Hz, H_4''), 3.34 (t, $J = 8.0$ Hz, H_5''). ^{13}C NMR (100 MHz, $CDCl_3$) δ 161.7, 145.8, 140.8, 137.0, 132.9, 125.0, 121.5, 99.5, 63.6, 33.0. HRMS (ESI) m/z $[M+H]^+ = 322.9951$ (found), $[M+H]^+ = 322.9961$ (calculated).

2-(5-amino-1-(3-bromophenyl)-1H-pyrazol-4-yl)-4,5-dihydrothiazole (1j)

Yield: 93%. m.p.: 171–173 °C. FT-IR ν (cm^{-1}): 3327, 3250, 3149, 3068, 2934, 2849, 1599, 1542–1440. 1H NMR (400 MHz, $CDCl_3$) δ 7.78 (t, $J = 1.9$ Hz, H_2'), 7.60 (s, H_3), 7.55–7.50 (m, H_4' , H_6'), 7.37 (t, $J = 8.0$ Hz, H_5'), 5.72 (br, NH_2), 4.33 (t, $J = 8.1$ Hz, H_4''), 3.34 (t, $J = 8.1$ Hz, H_5''). ^{13}C NMR (100 MHz, $CDCl_3$) δ 161.7, 145.9, 140.9, 139.2, 130.9, 130.8, 126.6, 123.3, 121.7, 99.5, 63.7, 33.0. HRMS (ESI) m/z $[M+H]^+ = 322.9961$ (found), $[M+H]^+ = 322.9961$ (calculated).

2-(5-amino-1-(4-methoxyphenyl)-1H-pyrazol-4-yl)-4,5-dihydrothiazole (1k)

Yield: 76%. m.p.: 164–166 °C. FT-IR ν (cm^{-1}): 3381, 3277, 3200, 3129, 3078, 2994, 2941, 2833, 1605, 1541–1434. 1H NMR (500 MHz, $CDCl_3$) δ 7.58 (s, H_3), 7.45 (d, $J = 8.7$ Hz, H_2' , H_6'), 7.01 (d, $J = 8.7$ Hz, H_3' , H_5'), 5.54 (br, NH_2), 4.32 (t, $J = 8.0$ Hz, H_4''), 3.85 (s, CH_3), 3.33 (t, $J = 8.0$ Hz, H_5''). ^{13}C NMR (125 MHz, $CDCl_3$) δ 162.0, 159.5, 146.1, 140.3, 130.9, 125.8, 115.1, 99.1, 63.8, 55.8, 33.2. HRMS (ESI) m/z $[M+H]^+ = 275.0963$ (found), $[M+H]^+ = 275.0961$ (calculated).

2-(5-amino-1-(2,3-dichlorophenyl)-1H-pyrazol-4-yl)-4,5-dihydrothiazole (1l)

Yield: 86%. m.p.: 188–190 °C. FT-IR ν (cm^{-1}): 3330, 3242, 3136, 2940, 2844, 1604, 1582–1433. 1H NMR (400 MHz, $CDCl_3$) δ 7.65 (s, H_3), 7.62 (dd, $J = 7.7, 2.0$ Hz, H_4'), 7.42–7.34 (m, H_5' , H_6'), 5.51 (br, NH_2), 4.33 (t, $J = 8.0$ Hz, H_4''), 3.35 (t, $J = 8.0$ Hz, H_5''). ^{13}C NMR (100 MHz, $CDCl_3$) δ 161.8, 147.0, 141.1, 136.6, 134.6, 131.7, 131.4, 128.2, 128.1, 98.4, 63.6, 33.1. HRMS (ESI) m/z $[M+H]^+ = 313.0072$ (found), $[M+H]^+ = 313.0076$ (calculated).

2-(1-phenyl-1H-pyrazol-4-yl)-4,5-dihydrothiazole (2a)

Yield: 78%. m.p.: 112–114 °C. FT-IR ν (cm^{-1}) 3135, 3060, 2955, 2851, 1618, 1595–1500. 1H NMR (400 MHz, $CDCl_3$) δ 8.37 (s, H_5), 8.05 (s, H_3), 7.72 (dd, $J = 8.0; 1.0$ Hz, H_2' , H_6'), 7.48 (t, $J = 8.0$ Hz, H_3' , H_5'), 7.34 (t, $J = 8.0$ Hz, H_4'), 4.40 (t, $J = 8.2$ Hz, H_4''), 3.44 (t, $J = 8.2$ Hz, H_5''). ^{13}C NMR (100 MHz, $CDCl_3$) δ 160.6, 140.6, 139.5, 129.6, 127.5, 127.3, 119.4, 118.7, 64.0, 33.7. HRMS (ESI) m/z $[M+H]^+ = 230.0747$ (found), $[M+H]^+ = 230.0746$ (calculated).

2-(1-(3-chlorophenyl)-1H-pyrazol-4-yl)-4,5-dihydrothiazole (2b)

Yield: 91%. m.p.: 88–90 °C. FT-IR ν (cm^{-1}): 3136, 3062, 2958, 2847, 1616, 1589–1463. 1H NMR (400 MHz, $CDCl_3$) δ 8.36 (s, H_5), 8.05 (s, H_3), 7.78 (t, $J = 2.0$ Hz, H_2'), 7.60 (ddd, $J = 8.1; 2.0; 1.0$ Hz, H_6'), 7.41 (t, $J = 8.1$ Hz, H_5'), 7.31 (ddd, $J = 8.1; 2.0; 1.0$ Hz, H_4'), 4.40 (t, $J = 8.3$ Hz, H_4''), 3.45 (t, $J = 8.3$ Hz, H_5''). ^{13}C NMR (100 MHz, $CDCl_3$) δ 160.4, 140.9, 140.3,

135.5, 130.6, 127.5, 127.3, 119.7, 119.2, 117.2, 64.0, 33.8. HRMS (ESI) m/z $[M+H]^+$ = 264.0348 (found), $[M+H]^+$ = 264.0357 (calculated).

2-(1-(2,4-dichlorophenyl)-1H-pyrazol-4-yl)-4,5-dihydrothiazole (2c)

Yield: 73%. m.p.: 96–98 °C. FT-IR ν (cm^{-1}): 3135, 3044, 2952, 2849, 1624, 1545–1428. ^1H NMR (400 MHz, CDCl_3) δ 8.24 (s, H_5), 8.07 (s, H_3), 7.56–7.54 (m, H_3' , H_6'), 7.38 (dd, J = 8.6; 2.3 Hz, H_5'), 4.39 (t, J = 8.2 Hz, H_4''), 3.43 (t, J = 8.2 Hz, H_5''). ^{13}C NMR (100 MHz, CDCl_3) δ 159.9, 140.6, 136.2, 134.9, 131.9, 130.5, 129.0, 128.4, 128.1, 118.6, 64.4, 33.8. HRMS (ESI): m/z $[M+H]^+$ = 297.9966 (found), $[M+H]^+$ = 297.9967 (calculated).

2-(1-(3,5-dichlorophenyl)-1H-pyrazol-4-yl)-4,5-dihydrothiazole (2d)

Yield: 83%. m.p.: 134–136 °C. FT-IR ν (cm^{-1}): 3172, 3071, 2945, 2853, 1625, 1583–1441. ^1H NMR (500 MHz, CDCl_3) δ 8.34 (s, H_5), 8.06 (s, H_3), 7.66 (s, H_2' , H_6'), 7.32 (s, H_4'), 4.40 (t, J = 8.3 Hz, H_4''), 3.46 (t, J = 8.3 Hz, H_5''). ^{13}C NMR (125 MHz, CDCl_3) δ 160.4, 141.5, 141.0, 136.3, 127.8, 127.3, 119.8, 117.9, 64.3, 34.0. HRMS (ESI) m/z $[M+H]^+$ = 297.9962 (found), $[M+H]^+$ = 297.9967 (calculated).

2-(1-(3,4-dichlorophenyl)-1H-pyrazol-4-yl)-4,5-dihydrothiazole (2e)

Yield: 73%. m.p.: 142–144 °C. FT-IR ν (cm^{-1}): 3132, 3065, 2939, 2853, 1615, 1596–1433. ^1H NMR (400 MHz, CDCl_3) δ 8.32 (s, H_5), 8.05 (s, H_3), 7.89 (dd, J = 2.1; 0.5 Hz, H_2'), 7.56–7.55 (m, H_5' , H_6'), 4.40 (t, J = 8.3 Hz, H_4''), 3.45 (t, J = 8.3 Hz, H_5''). ^{13}C NMR (100 MHz, CDCl_3) δ 155.3, 136.3, 133.8, 129.0, 126.5, 126.4, 122.6, 116.5, 114.7, 113.4, 59.4, 29.1. HRMS (ESI) m/z $[M+H]^+$ = 297.9967 (found), $[M+H]^+$ = 297.9967 (calculated).

2-(1-(4-chlorophenyl)-1H-pyrazol-4-yl)-4,5-dihydrothiazole (2f)

Yield: 85%. m.p.: 130–133 °C. FT-IR ν (cm^{-1}): 3130, 3061, 2936, 2854, 1623, 1545–1500. ^1H NMR (500 MHz, CDCl_3) δ 8.32 (s, H_5), 8.04 (s, H_3), 7.66 (d, J = 8.8 Hz, H_2' , H_6'), 7.45 (d, J = 8.8 Hz, H_3' , H_5'), 4.39 (t, J = 8.2 Hz, H_4''), 3.44 (t, J = 8.2 Hz, H_5''). ^{13}C NMR (125 MHz, CDCl_3) δ 160.4, 141.0, 138.2, 133.1, 129.9, 127.6, 120.7, 119.4, 64.4, 34.0. HRMS (ESI) m/z $[M+H]^+$ = 264.0349 (found), $[M+H]^+$ = 264.0357 (calculated).

2-(1-(4-fluorophenyl)-1H-pyrazol-4-yl)-4,5-dihydrothiazole (2g)

Yield: 71%. m.p.: 131–133 °C. FT-IR ν (cm^{-1}): 3130, 3059, 2995, 2850, 1618, 1543–1511. ^1H NMR (500 MHz, CDCl_3) δ 8.28 (s, H_5), 8.03 (s, H_3), 7.68 (dd, J = 8.4; 4.5 Hz, H_2' , H_6'), 7.17 (t, J = 8.4 Hz, H_3' , H_5'), 4.39 (t, J = 8.2 Hz, H_4''), 3.43 (t, J = 8.2 Hz, H_5''). ^{13}C NMR (125 MHz, CDCl_3) δ 161.8 (d, J = 247.3 Hz), 160.4, 140.8, 136.1, 127.7, 121.5 (d, J = 8.4 Hz), 119.2, 116.7 (d, J = 23.1 Hz), 64.5, 34.0. HRMS (ESI) m/z $[M+H]^+$ = 248.0642 (found); $[M+H]^+$ = 248.0652 (calculated).

2-(1-(3-fluorophenyl)-1H-pyrazol-4-yl)-4,5-dihydrothiazole (2h)

Yield: 91%. m.p.: 92–94 °C. FT-IR ν (cm^{-1}): 3136, 3062, 2952, 2850, 1610, 1600–1479. ^1H NMR (500 MHz, CDCl_3) δ 8.35 (s, H_5), 8.05 (s, H_3), 7.51–7.48 (m, H_5' , H_6'), 7.45–7.41 (m, H_2'), 7.04 (t, J = 7.5 Hz, H_4'), 4.40 (t, J = 8.2 Hz, H_4''), 3.44 (t, J = 8.2 Hz, H_5''). ^{13}C NMR (125 MHz, CDCl_3) δ 163.4 (d, J = 246.0 Hz), 160.5, 141.1, 141.0 (d, J = 10.2 Hz), 131.1 (d, J = 9.0 Hz), 127.7, 119.4, 114.7 (d, J = 3.0 Hz), 114.3 (d, J = 21.3 Hz), 107.4 (d, J = 26.5 Hz), 64.4, 34.0. HRMS (ESI) m/z $[M+H]^+$ = 248.0653 (found), $[M+H]^+$ = 248.0652 (calculated).

2-(1-(4-bromophenyl)-1H-pyrazol-4-yl)-4,5-dihydrothiazole (2i)

Yield: 78%. m.p.: 124–126 °C. FT-IR ν (cm^{-1}): 3132, 3060, 2990, 2844, 1614, 1545–1497. ^1H NMR (400 MHz, CDCl_3) δ 8.25 (s, H_5), 8.04 (s, H_3), 7.60 (s, H_2' , H_3' , H_5' , H_6'), 4.39 (t, J = 8.2 Hz, H_4''), 3.43 (t, J = 8.2 Hz, H_5''). ^{13}C NMR (100 MHz, CDCl_3) δ 159.6, 140.8, 138.5, 132.6, 127.1, 120.8, 120.6, 119.5, 64.6, 33.9. HRMS (ESI) m/z $[M+H]^+$ = 307.9848 (found), $[M+H]^+$ = 307.9852 (calculated).

2-(1-(3-bromophenyl)-1H-pyrazol-4-yl)-4,5-dihydrothiazole (2j)

Yield: 78%. m.p.: 104–106 °C. FT-IR ν (cm⁻¹): 3136, 3062, 2936, 2845, 1616, 1582–1459. ¹H NMR (400 MHz, CDCl₃) δ 8.26 (s, H₅), 8.05 (s, H₃), 7.93 (t, J = 2.0 Hz, H₂'), 7.64 (ddd, J = 8.0; 2.0; 1.0 Hz, H₆'), 7.46 (ddd, J = 8.0; 2.0; 1.0 Hz, H₄'), 7.34 (t, J = 8.0 Hz, H₅'), 4.39 (t, J = 8.2 Hz, H₄''), 3.43 (t, J = 8.2 Hz, H₅''). ¹³C NMR (100 MHz, CDCl₃) δ 159.5, 140.8, 140.5, 130.9, 130.2, 127.3, 123.3, 122.6, 119.5, 117.6, 64.6, 33.9. HRMS (ESI) m/z [M+H]⁺ = 307.9842 (found), [M+H]⁺ = 307.9852 (calculated).

2-(1-(4-methoxyphenyl)-1H-pyrazol-4-yl)-4,5-dihydrothiazole (2k)

Yield: 90%. m.p.: 114–116 °C. FT-IR ν (cm⁻¹): 3128, 3060, 2957, 2840, 1617, 1544–1458. ¹H NMR (400 MHz, CDCl₃) δ 8.19 (s, H₅), 8.01 (s, H₃), 7.60 (d, J = 9.0 Hz, H₂', H₆'), 6.98 (d, J = 9.0 Hz, H₃', H₅'), 4.38 (t, J = 8.2 Hz, H₄''), 3.85 (s, CH₃), 3.41 (t, J = 8.2 Hz, H₅''). ¹³C NMR (100 MHz, CDCl₃) δ 159.9, 158.8, 140.1, 133.2, 127.2, 121.1, 118.7, 114.6, 64.6, 55.6, 33.8. HRMS (ESI) m/z [M+H]⁺ = 260.0856 (found), [M+H]⁺ = 260.0852 (calculated).

2-(1-(2,3-dichlorophenyl)-1H-pyrazol-4-yl)-4,5-dihydrothiazole (2l)

Yield: 82%. m.p.: 112–114 °C. FT-IR ν (cm⁻¹): 3098, 3068, 2949, 2856, 1627, 1583–1428. ¹H NMR (400 MHz, CDCl₃) δ 8.20 (s, H₅), 8.07 (s, H₃), 7.56 (dd, J = 8.0; 1.3 Hz, H₄'), 7.50 (dd, J = 8.0; 1.3 Hz, H₆'), 7.34 (t, J = 8.0 Hz, H₅'), 4.39 (t, J = 8.2 Hz, H₄''), 3.43 (t, J = 8.2 Hz, H₅''). ¹³C NMR (100 MHz, CDCl₃) δ 159.8, 140.7, 139.4, 134.7, 132.1, 130.8, 128.2, 127.9, 126.3, 118.9, 64.9, 34.1. HRMS (ESI) m/z [M+H]⁺ = 297.9964 (found), [M+H]⁺ = 297.9967 (calculated).

2.2. Cell Culture

Vero cells, obtained from the Rio de Janeiro Cell Bank (BCRJ code 0245), were dissociated with trypsin–EDTA solution (0.025%), and maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS) at 37 °C in a humidified atmosphere of 5% CO₂.

Tridimensional Vero cell cultures were obtained as previously described [31]. Briefly, the isolated cells (2×10^4 /well) were cultured in 96-well U-bottom plates previously coated with 1% agarose. The spheroids were kept for 5 days at 37 °C in RPMI 1640 medium supplemented with 10% FBS for complete three-dimensional organization. Both 2D and 3D culture models were used for trypanocidal activity assays.

2.3. Parasite

The screening assays were performed with *T. cruzi* clone Dm28c (TcI) genetically modified to express luciferase gene (Dm28c-Luc), kindly provided by Dr. Cristina Henriques [34,35]. Trypomastigotes were isolated from *T. cruzi*-infected Vero cell monolayers (10:1 parasites/host cell ratio). On the 4th day post-infection (dpi), free trypomastigotes in the culture supernatant were harvested, and the number of parasites/mL was quantified in a Neubauer chamber [36].

2.4. Cytotoxicity In Vitro Assay

The compound toxicity was evaluated in Vero cell cultures. Briefly, Vero cells were seeded in 96-well white culture plates at a density of 1.5×10^4 cells/well for 24 h at 37 °C and 5% CO₂. Thereafter, the cell monolayers were washed with phosphate-buffered saline (PBS) and 200 μ L of fresh medium with a serial dilution of the pyrazole-thiazoline derivatives and Bz (1.9–500 μ M) added. The cell viability was determined by luminescent assay using the CellTiter-Glo Kit (Promega Corporation, Madison, WI, USA) based on the ATP level [31,36]. After 72 h of treatment, 20 μ L of CellTiter-Glo solution was added per well, and cultures were kept for 2 min under agitation. The luminescent signal was read on the GloMax reader (Promega Corporation, Madison, WI, USA). The concentration of compounds that reduced 50% of cell viability (CC₅₀) was calculated by linear regression. At least three independent assays were performed in duplicate.

All compound stock solutions were prepared at 100 mM in dimethyl sulfoxide (DMSO). The final DMSO concentration for the controls and drug treatment did not exceed 1%.

2.5. Antiparasitic Assay

The trypanocidal activity of the pyrazole-thiazoline derivatives was evaluated against trypomastigote and intracellular amastigote forms of *T. cruzi* (Dm28c-Luc). Tissue-derived trypomastigotes (1×10^6 parasites/well) were incubated with pyrazole-thiazoline derivatives and Bz in different concentrations (0.41–100 μ M) for 24 h at 37 °C in a humidified atmosphere and 5% CO₂. The parasite viability was determined by the addition of luciferin (300 μ g/mL), followed by luminescence detection on the GloMax microplate reader (Promega Corporation, Madison, WI, USA) [31,36]. The susceptibility of intracellular amastigotes to pyrazole-thiazoline derivatives (series 1 and 2) was evaluated using 24 h *T. cruzi*-infected Vero cell monolayers (10:1 parasite/host cell ratio). Then, the cultures were washed with PBS to remove non-internalized parasites, and 200 μ L of fresh medium with a serial dilution of pyrazole-thiazoline derivatives and Bz (0.41–100 μ M) was added for 72 h at 37 °C.

After 72 h of treatment, luciferin (300 μ g/mL) was added to the culture, and the viability of the parasites was assessed by reading the luminescent signal on the GloMax reader (Promega Corporation, Madison, WI, USA). Controls were also performed in non-toxic concentrations of DMSO ($\leq 1\%$). The concentration that reduces the number of viable parasites by 50% (IC₅₀) or 90% (IC₉₀) was calculated by linear regression. The selectivity index (SI) was calculated as CC₅₀/IC₅₀ for each parasite form.

2.6. Reversibility Assays

Vero cell cultures infected with *T. cruzi* Dm28c-Luc, as previously described, were incubated for 72 h at 37 °C, with the promising derivatives at concentrations higher than IC₉₀ [31]. Then, the cultures were washed with PBS, and maintained for another 72 h at 37 °C in a drug-free medium. Trypomastigotes released in the culture supernatant were detected by transferring the culture medium to 96-well plates, followed by luciferin (300 μ g/mL) addition. Viable intracellular amastigotes were also accessed by adding luciferin solution to the cell monolayers. The luminescence signal, revealing viable parasites, was read on the GloMax microplate reader (Promega Corporation, Madison, WI, USA).

2.7. 3D Culture Model

Vero cell spheroids were infected for 24 h with 2×10^5 trypomastigotes (Dm28c-Luc). After washing, to remove the non-internalized parasites, the 3D cultures were treated for 72 h at 37 °C, with the promising derivatives in concentrations higher than IC₉₀ [31]. Parasite load was assessed by the luminescence reaction after adding the luciferase substrate (luciferin 300 μ g/mL). In addition, fluorescence microscopy images of untreated and treated *T. cruzi*-infected spheroids were acquired after fixing the cultures with 4% paraformaldehyde in PBS and 4',6-diamidino-2-phenylindole (DAPI) staining, a DNA dye. The samples were observed under the Zeiss Axio Imager M2 fluorescence microscope (Carl Zeiss, Baden-Württemberg, Germany).

2.8. In Vitro Combination Therapy

In vitro combination treatment between promising candidates and Bz was performed against intracellular amastigotes (Dm28c-Luc) using a modified fixed-ratio isobologram method [37]. The highest concentrations of the compounds were determined by ensuring that the IC₅₀ concentrations of the compounds in monotherapy were close to half of a series of eight serial dilutions (1:3). The first concentrations were prepared in the following ratios: 5:0, 5:1, 2:1, 1:2, 1:5, and 0:5 of Bz and promising candidates, respectively. Then, serial dilutions (1:3) of the proportions were made at eight points of dilution. Vero cell cultures infected with *T. cruzi* Dm28c-Luc were incubated with the compound combinations for 72 h. Two independent experiments in triplicate were performed. In each ratio, the IC₅₀ of each

compound was determined. The FICI (fractional inhibitory concentration index) of each IC_{50} was calculated as follows: IC_{50} when in combination/ IC_{50} of compound alone. The FICI sum ($\Sigma FICI$) was determined as: FICI drug A + FICI drug B. $x\Sigma FICI$ is the mean of the FICI sums (FICI). The isobologram graph was built plotting the FICI for each proportion of the compounds. The $x\Sigma FICI$ was used to classify the interaction as synergistic $x\Sigma FICI \leq 0.5$, no interaction $x\Sigma FICI > 0.5-4$, and antagonistic for $x\Sigma FICI > 4$ [38,39].

2.9. Measurement of Reactive Oxygen Species (ROS) Levels

The production of intracellular ROS was evaluated in trypomastigotes (7×10^6 parasites/well) treated for 1 h, 3 h, and 24 h at 37 °C, with promising derivatives in IC_{50} concentration. Then, the parasites were washed in PBS, and incubated for 30 min in the dark with 20 μM of 2',7'-dichlorodihydrofluorescein diacetate (H_2DCFDA). The fluorescence signal, generated by the oxidation of ROS sensitive probes, was measured using 485/535 nm excitation/emission wavelengths with a SpectraMax M2 microplate reader (Molecular Devices, San Jose, CA, USA). The fluorescence intensity of the blank was subtracted from all samples evaluated. Parasites incubated with 0.5% DMSO and 20 μM H_2O_2 were used as negative and positive controls, respectively [40].

2.10. In Silico Analysis

Physicochemical properties of promising candidates were calculated using OSIRIS DataWarrior software version 5.5.0 [41] and FAFDrugs4 [42]. The maps of molecular lipophilicity potential (MLP) were generated using Molinspiration Galaxy 3D Structure Generator v2021.01 beta [43]. DataWarrior was also used for the target search. First, molecules were retrieved within the ChEMBL database, annotated to target the *T. cruzi* parasite and proteins. Duplicity was removed, and then, scaffolds of pyrazole-thiazoline were queried against the small library of compounds. ADMET parameters (adsorption, distribution, metabolism, elimination, and toxicity) were acquired by inserting compounds' molecular structures in the ADMETsar platform [44].

2.11. Proteinase Activity in Solution


Trypomastigote protein extracts (Dm28c-Luc; 10^8 parasites/mL) were obtained as previously described [30]. The cysteine protease activity of the total protein extracts (5 μg) was measured using the reaction buffer (CH_3COONa 10 mM, pH 5.0 containing 1 mM DTT), in the presence of the fluorogenic peptide substrate (60 μM of 7-Amino-4-Methylcoumarin hydrochloride), CBZ-L-Phenylalanyl-L-Arginine amide (Z-FR-AMC), and serial dilutions of pyrazole-thiazolines derivatives (100–6.25 μM). The samples were incubated for 45 min at room temperature. The variation in arbitrary fluorescence units (AFU), corresponding to the enzymatic cleavage of the fluorogenic substrate, was monitored in a SpectraMax M2e reader (Molecular Devices, Sunnyvale, CA, USA) for 1 h, with excitation values at 370 nm and emission values at 460 nm. Extracts incubated with 0.5% DMSO or with cysteine protease inhibitor E-64 were used as positive and negative controls, respectively. Substrate self-degradation was monitored, and did not produce significant effects. The inhibitory activity was expressed as percentage inhibition [31].

3. Results and Discussion

3.1. Chemistry

The synthetic routes to obtain the derivatives 2-(5-amino-1-aryl-1H-pyrazole-4-yl)-4,5-dihydrothiazoles **1(a-l)** and 2-(1-aryl-1H-pyrazole-4-yl)-4,5-dihydrothiazoles **2(a-l)** are summarized in Scheme 1. Firstly, commercial arylhydrazine hydrochlorides **3(a-l)** reacted with sodium acetate, through an acid–base reaction, in ethanol. Right after that, ethoxymethylenemalononitrile was added to afford the key intermediates 5-amino-1-aryl-1H-pyrazole-4-carbonitriles **4(a-l)** in a 69–98% yield. Subsequently, **4(a-l)** were submitted to an aprotic deamination reaction with isobutyl nitrite and tetrahydrofuran to obtain the desired 1-aryl-1H-pyrazole-4-carbonitriles **5(a-l)** in excellent yields (80–98%). Finally, the

targets **1(a-l)** and **2(a-l)** were synthesized from **4(a-l)** and **5(a-l)**, respectively, through the reaction with 2-aminoethanethiol hydrochloride, potassium carbonate, and methanol as solvent. The compounds **1(a-l)** and **2(a-l)** were isolated in 76–94% and 71–91% yields, respectively. The structures of all of the newly synthesized derivatives, **1(a-l)** and **2(a-l)**, were confirmed by Fourier Transform Infrared (FTIR), ^1H , and ^{13}C Nuclear Magnetic Resonance (NMR), and High-Resolution Mass Spectrometry (HRMS) spectral analysis.



$\text{R}_1 = \text{a: H, b: 3-Cl, c: 2,4-diCl, d: 3,5-diCl, e: 3,4-diCl, f: 4-Cl, g: 4-F, h: 3-F, i: 4-Br, j: 3-Br, k: 4-OCH}_3, \text{l: 2,3-diCl}$.

Reagents and conditions: (i) sodium acetate, ethanol, 20 min; (ii) ethoxymethylenemalononitrile, 1 h, reflux; (iii) 2-aminoethanethiol hydrochloride, potassium carbonate, methanol, 3–6 h; (iv) isobutyl nitrite, THF, 2 h, reflux.

Scheme 1. Synthetic routes to obtain **1(a-l)** and **2(a-l)**.

3.2. Toxicity and Phenotypic Screening of Pyrazole-Thiazoline Derivatives

The trypanocidal effect of the two new pyrazole-thiazoline series, **1(a-l)** and **2(a-l)**, was evaluated against clinically relevant forms of *T. cruzi* (intracellular amastigotes and trypomastigotes) using a luminescent viability assay (Table 1). Most series 1 derivatives (amino-pyrazole-thiazoline) have low activity against trypomastigotes, showing IC_{50} values $\geq 49.3 \mu\text{M}$. From this series, only **1k** ($\text{IC}_{50} = 12.0 \pm 3.5 \mu\text{M}$) is highlighted for exhibiting higher trypanocidal activity than Bz ($\text{IC}_{50} = 19.6 \pm 2.3 \mu\text{M}$) (Table 1). However, **1k** showed a low effect against intracellular amastigotes, with an IC_{50} value of $79.1 \pm 4.4 \mu\text{M}$. Derivatives from series 1, **1(a-l)**, were not cytotoxic, with most analogues having a $\text{CC}_{50} > 500 \mu\text{M}$, but all compounds were less active than Bz ($\text{IC}_{50} = 3.3 \pm 1.1 \mu\text{M}$) for intracellular amastigotes (Table 1).

Interestingly, the removal of the amino group ($-\text{NH}_2$), giving rise to series 2, **2(a-l)**, increased the biological effect of the new derivatives, with some of them (**2b**, **2c**, and **2f**) exhibiting activity (IC_{50}) in the nM concentrations range. In general, the series 2 activity against trypomastigotes had IC_{50} values $< 10 \mu\text{M}$, except for the **2d** ($\text{IC}_{50} > 100$) and **2l** ($\text{IC}_{50} = 25.8 \pm 1.9 \mu\text{M}$) (Table 1). We highlight **2a** ($\text{IC}_{50} = 1.1 \pm 0.3 \mu\text{M}$), **2b** ($\text{IC}_{50} = 0.8 \pm 0.3 \mu\text{M}$), **2c** ($\text{IC}_{50} = 0.4 \pm 0.02 \mu\text{M}$), **2e** ($\text{IC}_{50} = 1.9 \pm 0.4 \mu\text{M}$), **2f** ($\text{IC}_{50} = 0.6 \pm 0.3 \mu\text{M}$), **2i** ($\text{IC}_{50} = 2.1 \pm 0.9 \mu\text{M}$), and **2k** ($\text{IC}_{50} = 3.1 \pm 0.3 \mu\text{M}$) with trypanocidal activity 6.3 to 49-fold greater than Bz ($\text{IC}_{50} = 19.6 \pm 2.3 \mu\text{M}$). For intracellular amastigotes, only **2c** ($\text{IC}_{50} = 1.4 \pm 0.4 \mu\text{M}$) had better trypanocidal activity than Bz ($\text{IC}_{50} = 3.3 \pm 1.1 \mu\text{M}$), reaching a selectivity index (SI) of 76.2 (Table 1). Some compounds, **2b**, **2c**, **2e**, **2f**, **2h**, **2i**, and **2j**, reached $\text{IC}_{50} < 10 \mu\text{M}$, but had different SI values. None of the derivatives (series 1 and 2) showed an IC_{90} value lower than Bz ($\text{IC}_{90} = 13.7 \pm 4.2 \mu\text{M}$) for intracellular amastigotes. Regarding cytotoxicity in Vero cells, series 2 has CC_{50} values ranging from 37.9 to 217.2 μM , except **2d** and **2e** ($\text{CC}_{50} > 500 \mu\text{M}$). Compounds **2c**, **2e**, and

2i stand out for their high SI (>30) for both trypomastigote and amastigote forms of *T. cruzi* (Table 1).

Table 1. Cytotoxicity and trypanocidal effect of pyrazole-thiazoline derivatives.

Compounds	Trypanocidal Activity (Mean ± SD μM)						Cytotoxicity (Mean ± SD μM)
	Trypomastigotes			Intracellular Amastigotes			Vero Cells
	IC ₅₀	IC ₉₀	SI	IC ₅₀	IC ₉₀	SI	CC ₅₀
1a	66.4 ± 2.7	>100	3.7	80.7 ± 3.9	>100	3.1	248.4 ± 22.0
1b	96.9 ± 3.1	>100	>5.2	95.7 ± 4.8	>100	5.2	>500
1c	>100	>100	<5	>100	>100	<5	>50
1d	>100	>100	>4.1	63.2 ± 5.4	>100	6.6	415.5 ± 34.6
1e	>100	>100	<5	>100	>100	<5	>500
1f	88.3 ± 7.1	>100	<5	>100	>100	<5	>500
1g	>100	>100	<5	96.3 ± 2.7	>100	5.6	483.0 ± 16.6
1h	>100	>100	<5	>100	>100	<5	>500
1i	49.3 ± 4.7	>100	>10.1	>100	>100	<5	>500
1j	52.3 ± 3.4	>100	>9.5	26.6 ± 3.1	>100	>18.7	>500
1k	12.5 ± 3.5	93.4 ± 5.5	>39.9	79.1 ± 4.4	97.3 ± 4.7	>6.3	>500
1l	>100	>100	<5	11.1 ± 2.0	>100	>44.9	>500
2A	1.1 ± 0.3	10.4 ± 1.1	166.8	10.7 ± 2.2	89.0 ± 2.6	17.4	187.3 ± 12.7
2b	0.8 ± 0.3	8.8 ± 1.3	100.2	8.3 ± 1.9	31.9 ± 1.3	9.4	78.3 ± 7.7
2c	0.4 ± 0.02	2.8 ± 0.6	269.9	1.4 ± 0.4	16.9 ± 2.5	76.2	106.7 ± 11.4
2d	>100	>100	<5	>100	>100	<5	>500
2e	1.9 ± 0.4	6.9 ± 2.0	>254	7.84 ± 1.0	30.4 ± 3.7	>62.9	>500
2f	0.6 ± 0.3	13.3 ± 2.3	143.6	7.6 ± 2.5	33.5 ± 4.4	12.0	91.7 ± 13.1
2g	7.9 ± 1.0	30.1 ± 2.8	7.3	14.0 ± 1.8	98.0 ± 3.4	4.18	58.6 ± 8.11
2h	9.8 ± 1.5	36.3 ± 3.2	3.8	9.1 ± 1.7	76.3 ± 6.1	4.19	37.9 ± 4.8
2i	2.1 ± 0.9	13.3 ± 2.8	101.2	6.8 ± 1.1	27.1 ± 3.6	31.8	217.2 ± 15.2
2j	9.1 ± 0.9	48.2 ± 4.1	7.11	8.1 ± 1.3	31.1 ± 3.1	7.9	64.5 ± 7.3
2k	3.1 ± 0.3	36.1 ± 2.6	36.1	22.4 ± 2.8	53.0 ± 9.8	4.9	110.1 ± 9.4
2l	25.8 ± 1.9	>100	3.44	25.3 ± 2.4	75.5 ± 8.3	3.5	88.7 ± 9.3
Bz	19.6 ± 2.3	95.9 ± 4.7	>18.9	3.3 ± 1.1	13.7 ± 4.2	>216	>500


Mean values of IC₅₀ and IC₉₀ from three independent experiments ± standard deviation (SD); IC₅₀: concentration that inhibits parasite proliferation by 50%; CC₅₀: concentration that reduces the viability of Vero cells by 50%; Nd = not determined; selectivity index (SI) = CC₅₀ of Vero cells/IC₅₀ of trypomastigote and intracellular amastigote forms of *T. cruzi*.

3.3. Structure–Activity Relationship Analysis

In an attempt to potentiate the activity of the 5-aminopyrazole-imidazoline compound (hit compound), the imidazoline ring was replaced by thiazoline, and different substituents were inserted into the phenyl ring. Also, the amine group (-NH₂) was introduced in series 1. In general, series 1 analogues showed lower potency (pIC₅₀ < 4.95) than series 2, demonstrating that the polar group in the pyrazole ring of this new molecule had a negative effect on biological activity (Table 2). In series 1, the introduction of the substituent 2,3-diCl (**1l**) on the phenyl ring increased the potency (pIC₅₀ = 4.95), whereas 2,4-diCl (**1c**), 3,4-diCl (**1e**), 4-Cl (**1f**), 3-F (**1h**), and 4-Br (**1i**) induced a drastic drop in potency (pIC₅₀ < 4).

Most series 2 derivatives have low micromolar activity. The insertion of chorine (**2b**, **2e**, and **2f**), fluorine (**2h**), or bromine (**2i** and **2j**) substituents resulted in compounds with similar pIC₅₀ values, around 5.0 (Table 2). An attempt to move 4-F and 4-Br to the 3- position was not beneficial. Also, fluorine (**2g** and **2h**) and bromine (**2j**) substitutions increased toxicity to Vero cells. The addition of 4-F (**2g**), 4-OCH₃ (**2k**), and 2,3-diCl (**2l**) decreased the potency (Table 2). The introduction of 3,5-diCl (**2d**) resulted in an even further decrease in potency (pIC₅₀ < 4). The 2,4-diCl substituted analogue (**2c**) achieved the best potency (pIC₅₀ = 5.85), showing a high selective index (SI = 76.2).

Table 2. Structure–activity relationship (SAR) analysis of pyrazole derivatives.



General Structure

Compounds	R ₁	R ₂	Intracellular Amastigotes pIC ₅₀
1a	H	NH ₂	4.09
1b	3-Cl	NH ₂	4.01
1c	2,4-diCl	NH ₂	<4
1d	3,5-diCl	NH ₂	4.19
1e	3,4-diCl	NH ₂	<4
1f	4-Cl	NH ₂	<4
1g	4-F	NH ₂	4.01
1h	3-F	NH ₂	<4
1i	4-Br	NH ₂	<4
1j	3-Br	NH ₂	4.57
1k	4-OCH ₃	NH ₂	4.10
1l	2,3-diCl	NH ₂	4.95
2a	H	H	4.97
2b	3-Cl	H	5.08
2c	2,4-diCl	H	5.85
2d	3,5-diCl	H	<4
2e	3,4-diCl	H	5.10
2f	4-Cl	H	5.11
2g	4-F	H	4.85
2h	3-F	H	5.04
2i	4-Br	H	5.16
2j	3-Br	H	5.09
2k	4-OCH ₃	H	4.64
2l	2,3-diCl	H	4.59
Bz	-	-	5.48

The effects of modifications in the R-groups of pyrazole-thiazoline derivatives are expressed as inhibitory potency values (pIC₅₀ = -log IC₅₀) against amastigote forms of *T. cruzi* (Dm28c-Luc clone). Higher values of pIC₅₀ indicate exponentially more potent inhibitors.

3.4. Physicochemical and ADMET Properties

The identification of three derivatives of series 2 (**2c**, **2e**, and **2i**) with potential trypanocidal activity, based on the IC₅₀ < 10 μM and SI > 20 criteria, led us to assess whether the selected candidates had a good oral bioavailability prediction. The in silico analysis showed no violation of Lipinski's rule of five (RO5), with molecular weight (MW) ranging from 308.20 to 298.19; a maximum lipophilicity (cLogP) value of 2.83; no more than 5 and 10 hydrogen bond donors (HBD) and acceptors, respectively; a reduced number of rotatable bonds (RB=2); and a topological polar surface area (TPSA) of 55.48 Å² (Figure 3). Distinct physicochemical parameters were noticed between promising pyrazole-thiazoline derivatives and Bz (Figure 3). Bz revealed low lipophilicity, and a high number of rotatable bonds (RB = 5), and did not satisfy the drug-likeness criteria. The radar chart showed that all derivatives fit the drug-likeness criteria, except for the saturation values (sp³ carbon fraction <0.25), suggestive of good oral bioavailability (Figure 3).




Figure 3. Physicochemical properties of promising pyrazole-thiazoline derivatives (**2c**, **2e**, **2i**) and Bz. (A) DataWarrior software was used to calculate and plot in 2D graphs the following physicochemical parameters: rotatable bonds, aqueous solubility (cLogS), hydrogen bond donors (HBD) and acceptors (HBA), lipophilicity (cLogP), molecular weight (MW), topological polar surface area (tPSA), and drug-likeness. (B) Radar plot representation of six physicochemical parameters (lipophilicity, size, polarity, solubility, flexibility, and saturation), calculated using SwissADME. In red, the threshold values to achieve the drug-likeness criteria.

Differences in the molecular lipophilicity potential (MLP) were observed between the pyrazole-thiazoline derivatives. Lipophilic regions coded with blue and violet color were mostly visualized in **2c** and **2e**, showing a prevalence of domains with a prediction of hydrophobic interactions which can favor the ligand–target binding (Figure 4). Interestingly, the polarity and lipophilicity are distinct between selected highly active compounds (**2c**, **2e**, and **2i**) and their lower active analogues (**1c**, **1e**, and **1i**), suggesting that, similar to cLogP, the distribution of hydrophilic and lipophilic domains in the molecular surface also interferes with the biological activity.

The in silico pharmacokinetic analysis of drug absorption revealed a prediction of diffusion across the blood–brain barrier (BBB), and good Caco-2 cell permeability and human intestinal (HIA) absorption (Supplementary Table S1). Pyrazole-thiazoline derivatives show a high probability to inhibit cytochrome P450 (CYP450) enzymes, such as CYP1A2, CYP2C19, and CYP2D6, with a prediction of low clearance. Most compounds showed a likelihood of hepatotoxicity, but only **2e** exhibited mutagenicity prediction. None of the compounds are predictive of human ether-à-go-go-related gene (hERG) cardiac potassium channel inhibition. Thus, the favorable prediction of physicochemical and ADMET parameters motivated us to validate the trypanocidal effect using more complex biological systems.




Figure 4. The molecular lipophilicity potential (MLP) of the promising pyrazole-thiazoline derivatives. Blue-violet color indicates the hydrophobic surface, intermediate lipophilic surfaces are coded by green, and yellow-orange colors represent the hydrophilic surface. Three-dimensional images were generated by Molinspiration Galaxy 3D Structure Generator v2018.01 beta (www.molinspiration.com, accessed on 10 December 2021).

3.5. Drug Efficacy on 3D Culture Model

The low success rate in the translation from in vitro biological activity into in vivo model efficacy led us to introduce the 3D culture model in our drug screening platform. Then, a 3D spheroids culture, which more accurately reflected human tissue complexity and the microenvironment, was employed to evaluate the efficacy of promising compound candidates. *T. cruzi*-infected 3D Vero cells were treated for 72 h with **2c**, **2e**, and **2i**, and parasite load was evaluated after luciferin addition. Parasite viability, assessed by luciferase activity, was determined by luminescence signal, represented as an arbitrary luminescence unit (ALU). A high parasite burden was observed in untreated spheroids ($ALU = 166,678 \pm 22,824$), which was significantly reduced after treatment with all promising candidates (Figure 5). Potent activity was demonstrated by **2c** at concentrations of 25 ($ALU = 3329 \pm 250$) and 50 μ M ($ALU = 1648 \pm 343$), resulting in approximately 98% inhibition compared to untreated *T. cruzi*-infected microtissue. Also, **2c** showed better efficacy even at lower concentrations (1.5–3 times IC_{90}). Compounds **2e** ($ALU = 15,110 \pm 1990$) and **2i** ($ALU = 25,788 \pm 2776$) also demonstrated effectiveness in reducing parasite viability in *T. cruzi*-infected microtissue, similarly to Bz-treated spheroids ($ALU = 20,024 \pm 2796$) (Figure 5).

The ability of promising compounds to eliminate intracellular parasites was also analyzed by fluorescence microscopy. DAPI staining images revealed a high parasite load in infected and untreated microtissues (Figure 6). A large number of intracellular amastigotes was clearly visualized throughout the untreated spheroid, even in the innermost layers. In contrast, Bz-treated microtissues demonstrated a drastic reduction in the infection profile, with few intracellular parasites visualized in the spheroids (Figure 6). Treatment with **2c**, **2e**, and **2i** also impacted the parasite clearance. Few parasites were visualized in the spheroid treated with **2c**, indicative of good permeability and activity of the compound in the microtissue. All pyrazole-thiazoline derivatives markedly reduced the parasite load in the microtissue (Figure 6), as revealed by arbitrary luminescent data (Figure 5).




Figure 5. Effect of promising candidates, **2c**, **2e**, and **2i**, in *T. cruzi*-infected microtissue. Trypanocidal activity, represented as arbitrary luminescence unit (ALU), correlates to the luminescent signal proportional to the number of viable parasites (Dm28c-Luc). All compounds significantly decreased the parasite load in microtissue compared to control, showing a similar efficacy to Bz treatment. Statistical significance, in relation to the untreated group, was determined using the One-Way ANOVA test, with $p < 0.001$ (***).




Figure 6. Analysis of **2c**, **2e**, and **2i** efficacy on *T. cruzi*-infected microtissues. (A–E) DAPI staining images

images of the whole infected spheroids untreated (A) and treated with Bz (B), 2c (C), 2e (D), and 2i (E). (A1–E1) Representative areas of infected microtissues, highlighting the nucleus of the host cells, and the nucleus and kinetoplast of intracellular amastigotes (red arrowhead). (A1) Large amounts of intracellular amastigotes (red arrowhead) are visualized in *T. cruzi*-infected microtissue without treatment (control). (B1) Bz treatment (100 μ M) showed a drastic reduction in the infection profile, with few intracellular parasites (red arrowhead). (C1) Treatment with 2c (50 μ M) showed a similar effect to Bz with rare parasites. Treatment with 2e (D1) and 2i (E1) at 100 μ M concentration also revealed a reduction in parasite load. Bars: 50 μ m (A–E) and 10 μ m (A1–E1).

3.6. Potential of Pyrazole-Thiazoline Derivatives to Prevent Parasite Resurgence and the Effect in Combination Therapy

An important issue was to assess the compound activity reversibility. Then, the selected candidates (2c, 2e, and 2i) were evaluated for a prolonged period of time in order to assess their efficacy under drug-free conditions. Drug treatment was performed for 72 h at concentrations ranging from 1.5 to 7.2-fold the IC₉₀ value, respecting their toxicity levels in mammalian cells (CC₅₀). Most compounds were tested at 100 μ M, except for 2c, whose maximum concentration reached 50 μ M. The trypanocidal effect was analyzed after drug washing and 3 days exposure in the absence of compounds. None of the pyrazole-thiazoline derivatives led to the suppression of parasitism, but all selected compounds significantly reduced the parasite load (Figure 7).




Figure 7. Analysis of 2c, 2e, and 2i treatment on parasite recrudescence in vitro. After 72 h treatment, the compounds were removed, and after culture washing, drug-free medium was added for an additional 72 h culture. The luminescent signal, corresponding to parasite viability, was performed on both supernatant (A) and *T. cruzi*-infected Vero cell monolayers (B). Statistical significance, in relation to the untreated group, was determined using the One-Way ANOVA test, with $p < 0.001$ (***).

Bz treatment (100 μM) sustained the parasite clearance in both supernatant and cell monolayers. Compounds **2c** (50 μM) and **2i** (100 μM) were the most effective in controlling the intracellular amastigotes proliferation, inhibiting 78% and 89% of cell monolayer infection, respectively, compared to **2e** (69% inhibition) (Figure 7). Among the pyrazole-thiazoline derivatives, **2c** stands out for reducing by 85% the release of trypomastigotes in the culture supernatant (Figure 7). It is possible that prolonged treatment with the drug-containing medium replacement may improve the trypanocidal activity of promising candidates. It was shown that Bz treatment for 16 days of *T. cruzi*-infected Vero cell monolayers (strain Silvio X10/7) resulted in the prevention of spontaneous parasite relapse for up to 60 days, whereas posaconazole was unable to achieve parasite clearance [45].

The **2c** showing better activity against trypomastigotes ($\text{IC}_{50} = 0.4 \mu\text{M}$) and intracellular amastigotes ($\text{IC}_{50} = 1.4 \mu\text{M}$), and even better potency ($\text{pIC}_{50} = 5.85$) than Bz ($\text{pIC}_{50} = 5.48$), motivated us to investigate whether the combination of **2c** and Bz could potentiate the trypanocidal activity. The in vitro effect of the Bz and **2c** combined treatment against intracellular amastigotes was analyzed by a luminescent assay, using *T. cruzi* Dm28c-Luc. The drug pairs were combined at four different ratios in accordance with the previously determined IC_{50} and FICI, ΣFICI , and $x\Sigma\text{FICI}$ values calculated. The $x\Sigma\text{FICI}$ value of 1.11 indicates no interaction between compounds **2c** and Bz in combined treatment (Figure 8). The isobologram, with ΣFICI values greater than 0.99 in all proportions, depicts the absence of an interaction in all proportions evaluated (Figure 8).




Figure 8. In vitro combinatorial activity of **2c** and Bz against the amastigote forms of *T. cruzi*. FICI values were calculated based on IC_{50} values of combinations. Isobologram graph was plotted with FICI values.

3.7. Drug Target and Mechanism of Action

To evaluate if the insertion of the thiazoline group could change the pyrazole derivatives target that was previously identified as cruzipain, the compound scaffolds were queried in the ChEMBL database for similarity with different compounds with curated *T. cruzi* targets. One hit compound ($\text{IC}_{50} < 10 \mu\text{M}$) was similar (>0.8) to compound **2a**, and was annotated to target cruzipain (Figure 9). Despite similarity with **2a**, two other compounds had low activity against *T. cruzi*.




Figure 9. In silico analysis of pyrazole-thiazoline scaffolds using fragment-based search of molecular targets. The image shows matched scaffolds of pyrazole-thiazoline to trypanocidal compounds with different IC_{50} (nM) against annotated targets in the ChEMBL database. The analysis was performed using DataWarrior software, and three inhibitors of cruzipain were retrieved with similarity to pyrazole-thiazoline derivatives.

The prediction of cruzipain as a potential target of promising pyrazole-thiazoline derivatives motivated us to investigate whether the ligand–target interaction would promote inhibition of cysteine protease activity. Thus, the enzymatic activity was measured in the total protein extract of trypomastigotes, using Z-FR-AMC as fluorogenic substrate. Incubation with promising compounds did not induce significant changes in enzymatic activity. Derivatives **2c**, **2e**, and **2i** showed a maximum inhibition profile of 10% of cysteine protease activity, even at high concentrations of the compounds (100 μ M) (Figure 10). In contrast, E-64, a selective inhibitor of cysteine protease, inhibited the enzyme activity by more than 80% from the lowest concentration analyzed (6.25 μ M). Thus, the replacement of imidazoline by thiazoline in 5-amino-1-aryl-4-(4,5-dihydro-1H-imidazol-2-yl)-1H-pyrazole (hit compound) did not favor binding with the active site of cruzipain, despite the prediction of an extensive hydrophobic domain associated with the phenyl ring containing 2,4- and 3,4-diCl, **2c** and **2e**, respectively (Figure 4), as previously evidenced in the hit compound [30].




Figure 10. Analysis of the inhibitory activity of promising compounds on *T. cruzi* cysteine proteases. Protein extracts (5 μ g) of trypomastigote forms of *T. cruzi* were incubated with a series of dilutions (100–6.25 μ M) of pyrazole-thiazoline derivatives (**2c**, **2e**, and **2i**) and E-64, a specific inhibitor of cysteine proteases. The fluorescent signal resulting from the degradation of the fluorogenic substrate Z-FR-AMC (60 μ M) was quantified to determine the enzymatic activity. Results are presented as mean and standard deviation (\pm) of percent (%) enzyme activity from at least three independent experiments.

The failure to inhibit cysteine protease activity led us to assess whether the mechanism of action could be related to the induction of oxidative stress, since pyrazole derivatives have already been reported as iron-superoxide dismutase inhibitors [28,46]. Thus, the levels of reactive oxygen species (ROS) were evaluated using the 2, 7-dichlorofluorescein diacetate (H₂DCFDA) probe. The intracellular ROS level in trypomastigotes was measured after 1, 3, and 24 h of compound treatment. None of the derivatives were able to induce redox imbalance in the IC₅₀ concentration (Figure 11), indicating that another mechanism of action, not yet identified, is responsible for parasite death. Similar to Bz, which undergoes reductive metabolism to generate toxic intermediates that can act on redox metabolism, causes damage to DNA and RNA, and inhibits protein synthesis [47–49], the pyrazole-thiazoline derivatives or their metabolites may also act on multiple targets by interacting with proteins, or even forming adducts with nucleotides.




Figure 11. Analysis of reactive oxygen species (ROS) production in trypomastigote forms of *T. cruzi* treated with **2c**, **2e**, and **2i** for 1 h (A), 3 h (B), and 24 h (C) at IC₅₀ concentrations of each compound. The H₂DCFDA fluorescent probe was measured spectrofluorimetrically at 535 nm after excitation at 485 nm. Untreated and H₂O₂ (20 μM)-treated parasites were used as negative and positive controls, respectively. Data are expressed as normalized values for the negative (untreated) control. Statistical significance, in relation to the untreated group, was determined using the One-Way ANOVA test, with $p < 0.001$ (***)

The induction of apoptosis through ROS production and the activation of caspase 3 by pyrazole derivatives has been reported in breast cancer cells, surpassing the activity of the first-line drug, paclitaxel [24]. However, a potent antioxidant activity has also been highlighted for pyrazole hybrids through increased antioxidant enzymes, and reduced lipid peroxidation [50].

4. Conclusions

A new series of twenty-four pyrazole-thiazoline derivatives were synthesized and analyzed against *Trypanosoma cruzi*. Three analogues, **2c**, **2e**, and **2i**, showed potent activity against trypomastigotes (IC₅₀ ≤ 2.1 μM), and greater potency against intracellular amastigotes (pIC₅₀ > 5.16). The promising candidates showed good pharmacokinetic prediction and drug-likeness properties. The SAR analysis highlights the improvement of trypanocidal activity after removal of the amino group, and the inclusion of halogen substituents, such as chlorine and bromine, in the *para* position of the phenyl ring. Despite the inability to sterilize infected cultures in the washout assay, the selected derivatives, **2c**, **2e**, and **2i**, showed improved potency and marked trypanocidal activity in the microtissue, encouraging the design of novel pyrazole-thiazoline scaffolds to advance in the drug discovery pipeline for Chagas disease.

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/pharmaceutics14050995/s1>, Figure S1: NMR spectra of the compounds; Table S1: ADMET properties.

Author Contributions: Conceptualization, G.C.L., M.S.d.S. and M.C.d.S.P.; data curation, M.C.d.S.P.; formal analysis, G.C.L., L.d.S.L., M.S.d.S., and M.C.d.S.P.; funding acquisition, M.S.d.S. and M.C.d.S.P.; methodology, L.M.R.O., G.C.L., L.d.S.L., B.S.F., B.A.S., M.S.d.S., and M.C.d.S.P.; project administration, M.S.d.S. and M.C.d.S.P.; resources, M.S.d.S. and M.C.d.S.P.; supervision, M.C.d.S.P.; validation, M.C.d.S.P.; writing—original draft, M.C.d.S.P. and L.d.S.L.; writing—review and editing, G.C.L., L.d.S.L., M.S.d.S., and M.C.d.S.P. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by Oswaldo Cruz Institute-Fiocruz, Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) (grant 424015/2018-8 to M.C.d.S.P.), Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ) (grant E26/010.101050/2018 to M.C.d.S.P.). This work is a collaboration research project of members of the Rede Mineira de Química (RQ-MG), supported by FAPEMIG (Project: CEX-RED-00010-14 and Programa Primeiros Projetos CEX-APQ01014-14 to M.S.d.S.).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: The authors thank the Multi-user Research Facility of Bioassay and Flow Cytometry Platform and the Program for Technological Development in Tools for Health-RPT of Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro, Brazil, and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior-Brasil (CAPES)-Finance Code 001. The authors thank Jane Adlington for her thoughtful editorial oversight.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. WHO. Chagas Disease (American Trypanosomiasis). Available online: <http://www.who.int/mediacentre/factsheets/fs340/en/> (accessed on 3 February 2022).
2. Bocchi, E.A. Heart failure in South America. *Curr. Cardiol. Rev.* **2013**, *9*, 147–156. [CrossRef]
3. Avaria, A.; Ventura-Garcia, L.; Sanmartino, M.; Van der Laat, C. Population movements, borders, and Chagas disease. *Mem. Inst. Oswaldo Cruz* **2021**, *116*, e210151.
4. Arias, A.R.; Monroy, C.; Guhl, F.; Sosa-Estani, S.; Santos, W.S.; Abad-Franch, F. Chagas disease control-surveillance in the Americas: The multinational initiatives and the practical impossibility of interrupting vector-borne *Trypanosoma cruzi* transmission. *Mem. Inst. Oswaldo Cruz* **2021**, *116*, e210130.
5. Yasuda, M.A.S. Emerging and reemerging forms of *Trypanosoma cruzi* transmission. *Mem. Inst. Oswaldo Cruz* **2021**, *116*, e210033.
6. Rassi, A., Jr.; Rassi, A.; Marin-Neto, J.A. Chagas disease. *Lancet* **2010**, *375*, 1388–1402. [CrossRef]
7. Lidani, K.C.F.; Andrade, F.A.; Bavia, L.; Damasceno, F.S.; Beltrame, M.H.; Messias-Reason, I.J.; Sandri, T.L. Chagas disease: From discovery to a worldwide health problem. *Front. Public Health* **2019**, *7*, 166–179. [CrossRef] [PubMed]
8. Chadalawada, S.; Sillau, S.; Archuleta, S.; Mundo, W.; Bandali, M.; Parra-Henao, G.; Rodriguez-Morales, A.J.; Villamil-Gomez, W.E.; Suárez, J.A.; Shapiro, L.; et al. Risk of chronic cardiomyopathy among patients with the acute phase or indeterminate form of Chagas disease: A systematic review and meta-analysis. *JAMA Netw. Open.* **2020**, *3*, e2015072. [CrossRef]
9. Malone, C.J.; Nevis, I.; Fernández, E.; Sanchez, A. A Rapid Review on the Efficacy and Safety of Pharmacological Treatments for Chagas Disease. *Trop. Med. Infect. Dis.* **2021**, *12*, 128. [CrossRef]
10. Bern, C. Antitrypanosomal therapy for chronic Chagas' disease. *N. Engl. J. Med.* **2011**, *364*, 2527–2534. [CrossRef]
11. Nunes, M.C.; Dones, W.; Morillo, C.A.; Encina, J.J.; Ribeiro, A.L. Council on Chagas Disease of the Interamerican Society of Cardiology. Chagas disease: An overview of clinical and epidemiological aspects. *J. Am. Coll. Cardiol.* **2013**, *62*, 767–776. [CrossRef]
12. Echavarría, N.G.; Echeverría, L.E.; Stewart, M.; Gallego, C.; Saldarriaga, C. Chagas Disease: Chronic Chagas Cardiomyopathy. *Curr. Probl. Cardiol.* **2021**, *46*, 100507. [CrossRef] [PubMed]
13. Morillo, C.A.; Marin-Neto, J.A.; Avezum, A.; Sosa-Estani, S.; Rassi, A., Jr.; Rosas, F.; Villena, E.; Quiroz, R.; Bonilla, R.; Britto, C.; et al. Randomized trial of benznidazole for chronic Chagas' cardiomyopathy. *N. Engl. J. Med.* **2015**, *373*, 1295–1306. [CrossRef] [PubMed]
14. Molina, I.; Prat, J.G.; Salvador, F.; Treviño, B.; Sulleiro, E.; Serre, N.; Pou, D.; Roure, S.; Cabezas, J.; Valerio, L.; et al. Randomized trial of posaconazole and benznidazole for chronic Chagas' disease. *N. Engl. J. Med.* **2014**, *370*, 1899–1908. [CrossRef]
15. Torrico, F.; Gascon, J.; Ortiz, L.; Alonso-Vega, C.; Pinazo, M.J.; Schijman, A.; Almeida, A.C.; Alves, F.; Strub-Wourgaft, N.; Ribeiro, I.; et al. Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: A proof-of-concept, randomised, placebo-controlled trial. *Lancet Infect. Dis.* **2018**, *18*, 419–430. [CrossRef]

16. Morillo, C.A.; Waskin, H.; Sosa-Estani, S.; Del Carmen Bangher, M.; Cuneo, C.; Milesi, R.; Mallagray, M.; Apt, W.; Beloscar, J.; Gascon, J.; et al. Benznidazole and posaconazole in eliminating parasites in asymptomatic *T. cruzi* carriers. *J. Am. Coll. Cardiol.* **2017**, *69*, 939–947. [CrossRef]
17. Torrico, F.; Gascón, J.; Barreira, F.; Blum, B.; Almeida, I.C.; Alonso-Vega, C.; Barboza, T.; Bilbe, G.; Correia, E.; Garcia, W.; et al. New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): A phase 2, double-blind, randomised trial. *Lancet Infect. Dis.* **2021**, *21*, 1129–1140. [CrossRef]
18. Deeks, E.D. Fexinidazole: First global approval. *Drugs* **2019**, *79*, 215–220. [CrossRef]
19. DNDi. Drugs for Neglected Diseases Initiative. Fexinidazole for Chagas. Available online: <https://dndi.org/research-development/portfolio/fexinidazole-chagas/> (accessed on 3 February 2022).
20. Faria, J.V.; Vegi, P.F.; Miguita, A.G.C.; Dos Santos, M.S.; Boechat, N.; Bernardino, A.M.R. Recently reported biological activities of pyrazole compounds. *Bioorg. Med. Chem.* **2017**, *25*, 5891–5903. [CrossRef]
21. Silva, V.L.M.; Elguero, J.; Silva, A.M.S. Current progress on antioxidants incorporating the pyrazole core. *Eur. J. Med. Chem.* **2018**, *156*, 394–429. [CrossRef]
22. Yang, Z.; Li, P.; Gan, X. Novel Pyrazole-Hydrazone Derivatives Containing an Isoxazole Moiety: Design, Synthesis, and Antiviral Activity. *Molecules* **2018**, *23*, 1798. [CrossRef]
23. Alnufaie, R.; Raj, K.C.H.; Alsop, N.; Whitt, J.; Andrew Chambers, S.; Gilmore, D.; Alam, M.A. Synthesis and antimicrobial studies of Coumarin-substituted pyrazole derivatives as potent anti-*Staphylococcus aureus* agents. *Molecules* **2020**, *25*, 2758. [CrossRef] [PubMed]
24. Ashourpour, M.; Mostafavi Hosseini, F.; Amini, M.; Saeedian Moghadam, E.; Kazerouni, F.; Arman, S.Y.; Shahsavari, Z. Pyrazole Derivatives Induce Apoptosis via ROS Generation in the Triple Negative Breast Cancer Cells, MDA-MB. *Asian Pac. J. Cancer Prev.* **2021**, *22*, 2079–2087. [CrossRef] [PubMed]
25. Bekhit, A.A.; Nasralla, S.N.; El-Agroudy, E.J.; Hamouda, N.; El-Fattah, A.A.; Bekhit, S.A.; Amagase, K.; Ibrahim, T.M. Investigation of the anti-inflammatory and analgesic activities of promising pyrazole derivative. *Eur. J. Pharm. Sci.* **2022**, *168*, 106080. [CrossRef] [PubMed]
26. Da Silva, M.J.V.; Jacomini, A.P.; Gonçalves, D.S.; Pianoski, K.E.; Poletto, J.; Lazarin-Bidóia, D.; Volpato, H.; Nakamura, C.V.; Rosa, F.A. Discovery of 1,3,4,5-tetrasubstituted pyrazoles as anti-trypanosomatid agents: Identification of alterations in flagellar structure of *L. amazonensis*. *Bioorg. Chem.* **2021**, *114*, 105082. [CrossRef]
27. Camargo, J.N.A.; Pianoski, K.E.; Dos Santos, M.G.; Lazarin-Bidóia, D.; Volpato, H.; Moura, S.; Nakamura, C.V.; Rosa, F.A. Antiparasitic behavior of trifluoromethylated pyrazole 2-amino-1,3,4-thiadiazole hybrids and their analogues: Synthesis and structure-activity relationship. *Front. Pharmacol.* **2020**, *11*, 591570. [CrossRef]
28. Reviriego, F.; Olmo, F.; Navarro, P.; Marín, C.; Ramírez-Macías, I.; García-España, E.; Albelda, M.T.; Gutiérrez-Sánchez, R.; Sánchez-Moreno, M.; Arán, V.J. Simple dialkyl pyrazole-3,5-dicarboxylates show in vitro and in vivo activity against disease causing trypanosomatids. *Parasitology* **2017**, *144*, 1133–1143. [CrossRef]
29. Varghese, S.; Rahmani, R.; Russell, S.; Deora, G.S.; Ferrins, L.; Toynton, A.; Jones, A.; Sykes, M.; Kessler, A.; Eufrásio, A.; et al. Discovery of potent N-ethylurea pyrazole derivatives as dual inhibitors of *Trypanosoma brucei* and *Trypanosoma cruzi*. *ACS Med. Chem. Lett.* **2019**, *11*, 278–285. [CrossRef]
30. Monteiro, M.E.; Lechuga, G.; Lara, L.S.; Souto, B.A.; Viganó, M.G.; Bourguignon, S.C.; Calvet, C.M.; Oliveira, F.O.R., Jr.; Alves, C.R.; Souza-Silva, F.; et al. Synthesis, structure-activity relationship and trypanocidal activity of pyrazole-imidazoline and new pyrazole-tetrahydropyrimidine hybrids as promising chemotherapeutic agents for Chagas disease. *Eur. J. Med. Chem.* **2019**, *182*, 111610–111623. [CrossRef]
31. Orlando, M.L.R.; Lechuga, G.C.; Lara, L.S.; Ferreira, B.S.; Pereira, C.N.; Silva, R.C.; Santos, M.S.; Pereira, M.C.S. Structural optimization and biological activity of pyrazole derivatives: Virtual computational analysis, recovery assay and 3D culture model as potential predictive tools of effectiveness against *Trypanosoma cruzi*. *Molecules* **2021**, *26*, 6742. [CrossRef]
32. Santos, M.S.; Oliveira, M.L.; Bernardino, A.M.; de Léo, R.M.; Amaral, V.F.; de Carvalho, F.T.; Leon, L.L.; Canto-Cavalheiro, M.M. Synthesis and antileishmanial evaluation of 1-aryl-4-(4,5-dihydro-1H-imidazol-2-yl)-1H-pyrazole derivatives. *Bioorg. Med. Chem. Lett.* **2011**, *21*, 7451–7454. [CrossRef]
33. Santos, M.S.; Bernardino, A.M.R.; Pinheiro, L.C.S.; Canto-Cavalheiro, M.M.; Leon, L.L. An efficient synthesis of new 5-(1-Aryl-1H-pyrazole-4-yl)-1H-tetrazoles from 1-Aryl-1H-pyrazole-4-carbonitriles via [3 + 2] cycloaddition reaction. *J. Heterocycl. Chem.* **2012**, *49*, 1425–1428. [CrossRef]
34. Henriques, C.; Castro, D.P.; Gomes, L.H.F.; Garcia, E.S.; de Souza, W. Bioluminescent imaging of *Trypanosoma cruzi* infection in *Rhodnius prolixus*. *Parasites Vectors* **2012**, *5*, 214–229. [CrossRef] [PubMed]
35. Henriques, C.; Henriques-Pons, A.; Meuser-Batista, M.; Ribeiro, A.S.; de Souza, W. In vivo imaging of mice infected with bioluminescent *Trypanosoma cruzi* unveils novel sites of infection. *Parasites Vectors* **2014**, *7*, 89–104. [CrossRef] [PubMed]
36. Lara, L.S.; Lechuga, G.C.; Moreira, C.D.S.; Santos, T.B.; Ferreira, V.F.; da Rocha, D.R.; Pereira, M.C.S. Optimization of 1,4-naphthoquinone hit compound: A computational, phenotypic, and in vivo screening against *Trypanosoma cruzi*. *Molecules* **2021**, *26*, 423. [CrossRef]
37. Fivelman, Q.L.; Adagu, I.S.; Warhurst, D.C. Modified fixed-ratio isobologram method for studying in vitro interactions between atovaquone and proguanil or dihydroartemisinin against drug-resistant strains of *Plasmodium falciparum*. *Antimicrob. Agents Chemother.* **2004**, *48*, 4097–4102. [CrossRef]

38. Cardoso-Santos, C.; Fiuza, L.F.A.; Silva, C.F.; Mazzeti, A.L.; Girão, R.D.; Oliveira, G.M.; Batista, D.G.J.; Moreira, O.C.; Gomes, N.L.S.; Maes, L.; et al. 7-Aryl-7-deazapurine 3'-deoxyribonucleoside derivative as a novel lead for Chagas' disease therapy: In vitro and in vivo pharmacology. *JAC Antimicrob. Resist.* **2021**, *3*, 168–177. [[CrossRef](#)]
39. Odds, F.C. Synergy, antagonism, and what the checkerboard puts between them. *J. Antimicrob. Chemother.* **2003**, *52*, 1. [[CrossRef](#)]
40. Tomiotto-Pellissier, F.; Alves, D.R.; Miranda-Sapla, M.M.; de Moraes, S.M.; Assolini, J.P.; da Silva Bortoleti, B.T.; Gonçalves, M.D.; Cataneo, A.; Kian, D.; Madeira, T.B.; et al. *Caryocar coriaceum* extracts exert leishmanicidal effect acting in promastigote forms by apoptosis-like mechanism and intracellular amastigotes by Nrf2/HO-1/ferritin dependent response and iron depletion: Leishmanicidal effect of *Caryocar coriaceum* leaf extracts. *Biomed. Pharmacother.* **2018**, *98*, 662–672.
41. Sander, T.; Freyss, J.; von Korff, M.; DataWarrior, R.C. An open-source program for chemistry aware data visualization and analysis. *J. Chem. Inf. Model.* **2015**, *55*, 460–473. [[CrossRef](#)]
42. Lagorce, D.; Sperandio, O.; Baell, J.B.; Miteva, M.A.; Villoutreix, B.O. FAF-Drugs3: A web server for compound property calculation and chemical library design. *Nucleic Acids Res.* **2015**, *43*, W200–W207. [[CrossRef](#)]
43. Sumaryada, T.; Astarina, A.S.; Ambarsari, L. Molecular Docking and physicochemical analysis of the active compounds of Soursop (*Annonamuricata* Linn) for an anti-breast cancer agent. *Biointerface Res. Appl. Chem.* **2021**, *11*, 11380–11389.
44. Yang, H.; Lou, C.; Sun, L.; Li, J.; Cai, Y.; Wang, Z.; Li, W.; Liu, G.; Tang, Y. admetsAR 2.0: Web-service for prediction and optimization of chemical ADMET properties. *Bioinformatics* **2019**, *35*, 1067–1069. [[CrossRef](#)]
45. MacLean, L.M.; Thomas, J.; Lewis, M.D.; Cotillo, I.; Gray, D.W.; Rycker, M. Development of *Trypanosoma cruzi* in vitro assays to identify compounds suitable for progression in Chagas' disease drug Discovery. *PLoS Negl. Trop. Dis.* **2018**, *12*, e0006612. [[CrossRef](#)]
46. Sánchez-Moreno, M.; Marín, C.; Navarro, P.; Lamarque, L.; García-España, E.; Miranda, C.; Huertas, O.; Olmo, F.; Gómez-Contreras, F.; Pitarch, J.; et al. In vitro and in vivo trypanosomicidal activity of pyrazole-containing macrocyclic and macrobicyclic polyamines: Their action on acute and chronic phases of Chagas disease. *J. Med. Chem.* **2012**, *55*, 4231–4243. [[CrossRef](#)] [[PubMed](#)]
47. Hall, B.S.; Wilkinson, S.R. Activation of benzimidazole by trypanosomal type I nitroreductases results in glyoxal formation. *Antimicrob. Agents Chemother.* **2012**, *56*, 115–123. [[CrossRef](#)]
48. Goijman, S.G.; Stoppani, A.O. Effects of nitroheterocyclic drugs on macromolecule synthesis and degradation in *Trypanosoma cruzi*. *Biochem. Pharmacol.* **1985**, *34*, 1331–1336. [[CrossRef](#)]
49. Kasai, H.; Iwamoto-Tanaka, N.; Fukada, S. DNA modifications by the mutagen glyoxal: Adduction to G and C, deamination of C and GC and GA cross-linking. *Carcinogenesis* **1998**, *19*, 1459–1465. [[CrossRef](#)]
50. Ali, S.A.; Awad, S.M.; Said, A.M.; Mahgoub, S.; Taha, H.; Ahmed, N.M. Design, synthesis, molecular modelling and biological evaluation of novel 3-(2-naphthyl)-1-phenyl-1H-pyrazole derivatives as potent antioxidants and 15-Lipoxygenase inhibitors. *J. Enzym. Inhib. Med. Chem.* **2020**, *35*, 847–863. [[CrossRef](#)]